Samsung Biologics Maintains Dow Jones ESG Index Spot for Fifth Year

Event summary

  • Samsung Biologics included in Dow Jones Best-in-Class World Index for fifth consecutive year.
  • Recognition based on S&P Global Corporate Sustainability Assessment evaluating 2,500+ companies.
  • Company highlighted for supply chain management, environmental stewardship, and workplace safety improvements.
  • Received EcoVadis Platinum rating and sustainability award at CDMO Leadership Awards in 2026.
  • Global manufacturing capacity stands at 845,000 liters with plans for Bio Campus III expansion.

The big picture

Samsung Biologics' fifth consecutive inclusion in the Dow Jones ESG index underscores its leadership in sustainable biomanufacturing. As global investors increasingly prioritize ESG criteria, this recognition could enhance the company's competitive positioning in the contract development and manufacturing space. The company's focus on next-generation therapies and emerging modalities aligns with broader industry trends toward more complex, personalized treatments.

What we're watching

ESG Execution
Whether Samsung Biologics can sustain its ESG momentum amid increasing global standards.
Capacity Expansion
The pace at which Bio Campus III development will impact future contract wins.
Industry Benchmarking
How this recognition positions Samsung Biologics against competitors in CDMO sustainability rankings.